drugset / Trial / NCT06109428

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE

NCT06109428

Phase 4 Completed 30 enrolled Heron Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing abdominoplasty (Cohort 2).

Timeline

Start
2021-10-12
Primary completion
2022-03-29
Completion
2022-04-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 125 mg
Subject HTX-011 Unknown 400 mg
Background Acetaminophen Small molecule 1 g
Background Ibuprofen Small molecule 400 mg

Indications

No indication recorded.